HRT Financial’s Lexicon Pharmaceuticals LXRX Stock Holding History

HRT Financial’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$191K	Buy	122,780 +5,231	+4%	+$7.61K	﹤0.01%	3210
2025 Q4	$135K	Buy	117,549 +71,102	+153%	+$97.7K	﹤0.01%	2729
2025 Q3	$62K	Sell	46,447 -442,021	-90%	-$502K	﹤0.01%	2574
2025 Q2	$461K	Buy	+488,468	New	+$316K	﹤0.01%	1649
2024 Q2	–	Sell	-16,965	Closed	-$40K	–	2719
2024 Q1	$40K	Buy	+16,965	New	+$36.4K	﹤0.01%	1951
2023 Q3	–	Sell	-198,676	Closed	-$454K	–	2801
2023 Q2	$454K	Buy	+198,676	New	+$527K	﹤0.01%	1405
2022 Q4	–	Sell	-45,569	Closed	-$109K	–	2850
2022 Q3	$109K	Buy	+45,569	New	+$126K	﹤0.01%	2375
2022 Q2	–	Sell	-242,211	Closed	-$506K	–	3368
2022 Q1	$506K	Buy	242,211 +140,650	+138%	+$390K	﹤0.01%	1627
2021 Q4	$400K	Buy	+101,561	New	+$493K	﹤0.01%	2070
2020 Q3	–	Sell	-31,562	Closed	-$62K	–	2167
2020 Q2	$62K	Buy	+31,562	New	+$61.8K	﹤0.01%	1299
2019 Q4	–	Sell	-16,364	Closed	-$49K	–	1440
2019 Q3	$49K	Buy	+16,364	New	+$50.7K	﹤0.01%	1303

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial's LXRX Position: Q1 2026 in Review

HRT Financial increased its Lexicon Pharmaceuticals (LXRX) stake by 4.5% in Q1 2026, buying an estimated $7.61K and bringing the position to 122,780 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

HRT Financial first reported a position in LXRX in Q3 2019 and has held it in 11 quarters since. The position peaked at $506K in Q1 2022. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

HRT Financial held 122,780 shares of Lexicon Pharmaceuticals worth $191K as of Q1 2026.
HRT Financial bought 5,231 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $7.61K.
Lexicon Pharmaceuticals made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3210 holding.
HRT Financial first reported a position in Lexicon Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
HRT Financial's Lexicon Pharmaceuticals position peaked at $506K in Q1 2022.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.